Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Aterian Inc (ATER) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

Aterian (ATER) trades at $1.15, down 3.36% with a bullish technical signal despite negative profitability. Revenue has declined from $221M in 2022 to $69M in 2025, with net losses narrowing but persisting. The company is pursuing an asset sale, with proxy advisors recommending stockholders vote for transactions expected to return $0.85-$1.14 per share. Analyst sentiment is split evenly between Buy and Hold ratings.

The outlook hinges on the successful asset sale providing shareholder returns, but fundamental challenges remain with sustained losses and cash burn. Investment opportunity exists in the potential special dividend, while risks include ongoing operational losses and competitive pressures in consumer products.